Literature DB >> 30470408

Evidence for Improving Outcome Through Extent of Resection.

Shawn L Hervey-Jumper1, Mitchel S Berger2.   

Abstract

Surgical resection plays a central role in the management of gliomas however many tumors are within areas resulting in sensorimotor and cognitive consequences. This article reviews the evidence in support of extent of resection to improve survival, symptom management, and time to malignant transformation in low-grade gliomas. The authors summarize the evolving literature regarding the role of maximal safe resection in light of WHO subclassification of low-grade gliomas. Long lasting neurological deficits following glioma resection may hinder both survival and quality of life. New insights into glioma related central nervous system plasticity impact both surgical planning and timing of interventions.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Astrocytoma; Extent of resection; Low-grade glioma; Oligodendroglioma; Volume of residual

Mesh:

Year:  2018        PMID: 30470408     DOI: 10.1016/j.nec.2018.08.005

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  16 in total

1.  Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.

Authors:  S H Patel; A G Bansal; E B Young; P P Batchala; J T Patrie; M B Lopes; R Jain; C E Fadul; D Schiff
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

Review 2.  Tractography methods and findings in brain tumors and traumatic brain injury.

Authors:  Fang-Cheng Yeh; Andrei Irimia; Dhiego Chaves de Almeida Bastos; Alexandra J Golby
Journal:  Neuroimage       Date:  2021-10-18       Impact factor: 6.556

3.  Anatomically informed multi-level fiber tractography for targeted virtual dissection.

Authors:  Andrey Zhylka; Alexander Leemans; Josien P W Pluim; Alberto De Luca
Journal:  MAGMA       Date:  2022-07-29       Impact factor: 2.533

Review 4.  Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions.

Authors:  Kazuya Motomura; Fumiharu Ohka; Kosuke Aoki; Ryuta Saito
Journal:  Front Neurol       Date:  2022-05-12       Impact factor: 4.086

Review 5.  Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature-a systematic review of the literature.

Authors:  Lucas Alverne F Albuquerque; João Paulo Almeida; Leonardo José Monteiro de Macêdo Filho; Andrei F Joaquim; Hugues Duffau
Journal:  Neurosurg Rev       Date:  2020-08-07       Impact factor: 3.042

6.  Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.

Authors:  Kazuya Motomura; Lushun Chalise; Fumiharu Ohka; Kosuke Aoki; Kuniaki Tanahashi; Masaki Hirano; Tomohide Nishikawa; Junya Yamaguchi; Hiroyuki Shimizu; Toshihiko Wakabayashi; Ryuta Saito
Journal:  J Neurooncol       Date:  2021-05-19       Impact factor: 4.130

7.  Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery.

Authors:  Philip C De Witt Hamer; Philip C De Witt Hamer; Martin Klein; Shawn L Hervey-Jumper; Jeffrey S Wefel; Mitchel S Berger
Journal:  Neurosurgery       Date:  2021-03-15       Impact factor: 4.654

8.  Tumor Treating Fields : Additional Mechanisms and Additional Applications.

Authors:  Ashwin Kumaria
Journal:  J Korean Neurosurg Soc       Date:  2021-01-29

9.  Assessment of the Extent of Resection in Surgery of High-Grade Glioma-Evaluation of Black Blood Sequences for Intraoperative Magnetic Resonance Imaging at 3 Tesla.

Authors:  Tom Finck; Jens Gempt; Sandro M Krieg; Bernhard Meyer; Claus Zimmer; Benedikt Wiestler; Jan S Kirschke; Nico Sollmann
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

10.  Differences in the preferential location and invasiveness of diffuse low-grade gliomas and their impact on outcome.

Authors:  Francesco Latini; Markus Fahlström; Göran Hesselager; Maria Zetterling; Mats Ryttlefors
Journal:  Cancer Med       Date:  2020-06-14       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.